Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 2

Conditions

Keratosis, Actinic 2Keratosis 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × tirbanibulin × Clear all
NCT05741294 2025-02-20

A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Almirall, S.A.

Phase 4 Completed
334 enrolled 12 charts
Dermatologic

Keratosis, Keratosis, Actinic

NCT05260073 2024-09-20

PROAK

Almirall, S.A.

Completed
300 enrolled 9 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡